- Home
- ISRL vs ATRA Comparison
ISRL vs ATRA Comparison
Compare ISRL & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRL
- ATRA
- Stock Information
- Founded
- ISRL 2021
- ATRA 2012
- Country
- ISRL United States
- ATRA United States
- Employees
- ISRL N/A
- ATRA N/A
- Industry
- ISRL Blank Checks
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ISRL Finance
- ATRA Health Care
- Exchange
- ISRL Nasdaq
- ATRA Nasdaq
- Market Cap
- ISRL 79.7M
- ATRA 67.9M
- IPO Year
- ISRL 2023
- ATRA 2014
- Fundamental
- Price
- ISRL $12.65
- ATRA $11.89
- Analyst Decision
- ISRL
- ATRA Strong Buy
- Analyst Count
- ISRL 0
- ATRA 3
- Target Price
- ISRL N/A
- ATRA $21.00
- AVG Volume (30 Days)
- ISRL 2.2K
- ATRA 55.9K
- Earning Date
- ISRL 01-01-0001
- ATRA 11-11-2025
- Dividend Yield
- ISRL N/A
- ATRA N/A
- EPS Growth
- ISRL N/A
- ATRA N/A
- EPS
- ISRL 0.14
- ATRA 0.56
- Revenue
- ISRL N/A
- ATRA $188,667,000.00
- Revenue This Year
- ISRL N/A
- ATRA N/A
- Revenue Next Year
- ISRL N/A
- ATRA N/A
- P/E Ratio
- ISRL $93.55
- ATRA $21.27
- Revenue Growth
- ISRL N/A
- ATRA 202.41
- 52 Week Low
- ISRL $11.14
- ATRA $5.01
- 52 Week High
- ISRL $14.00
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- ISRL 53.41
- ATRA 49.31
- Support Level
- ISRL $11.99
- ATRA $11.70
- Resistance Level
- ISRL $12.70
- ATRA $12.22
- Average True Range (ATR)
- ISRL 0.11
- ATRA 0.63
- MACD
- ISRL 0.01
- ATRA -0.13
- Stochastic Oscillator
- ISRL 81.48
- ATRA 7.67
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).